trending Market Intelligence /marketintelligence/en/news-insights/trending/HrswPXHZMgG_QYEwy9spJg2 content esgSubNav
In This List

AbbVie ordered to pay $15M in birth defect trial

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


AbbVie ordered to pay $15M in birth defect trial

A federal jury asked AbbVie Inc. to pay $15 million in compensatory damages to Stevie Gonzalez, who was born with spina bifida, Reuters reported.

Spina bifida is a birth defect where there is an incomplete closing of the backbone and membranes around the spinal cord.

Gonzalez's mother blamed the 10-year-old boy's birth defect on Depakote in one of many lawsuits against AbbVie's bipolar disorder drug.

Christina Raquel said she was not adequately warned about a risk of birth defects when she took Depakote while pregnant.